A Hit-to-Lead optimisation programme was carried out on the adamantane high throughput screening hit 1 resulting in the discovery of a number of potent P2X(7) antagonists.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2003.08.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Applications of Machine Learning Approaches for the Discovery of SARS-CoV-2 PLpro Inhibitors.
J Chem Inf Model
January 2025
Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Rockville, Maryland 20850, United States.
The global impact of SARS-CoV-2 highlights the need for treatments beyond vaccination, given the limited availability of effective medications. While Pfizer introduced , an FDA-approved antiviral targeting the SARS-CoV-2 main protease (Mpro), this study focuses on designing new antivirals against another protease, papain-like protease (PLpro), which is crucial for viral replication and immune suppression. NCATS/NIH performed a high-throughput screen of ∼15,000 molecules from an internal molecular library, identifying initial hits with a 0.
View Article and Find Full Text PDFDiscovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach.
Acta Pharm Sin B
December 2024
State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Accurate receptor/ligand binding free energy calculations can greatly accelerate drug discovery by identifying highly potent ligands. By simulating the change from one compound structure to another, the relative binding free energy (RBFE) change can be calculated based on the theoretically rigorous free energy perturbation (FEP) method. However, existing FEP-RBFE approaches may face convergence challenges due to difficulties in simulating non-physical intermediate states, which can lead to increased computational costs to obtain the converged results.
View Article and Find Full Text PDFExploring target selectivity in designing and identifying PI3Kα inhibitors for triple negative breast cancer with fragment-based and bioisosteric replacement approach.
Sci Rep
January 2025
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
Triple-negative breast cancer (TNBC) is one of the most fatal malignancies in the world, accounting for 42% of all deaths due to metastasis. The significant development is hindered by the multi-drug resistance and poor patient compliance. PIK3CA gene mutation is one of the important causes of TNBC, which causes dysregulation of the cell cycle and cell proliferation.
View Article and Find Full Text PDFDeep Multitask Learning-Driven Discovery of New Compounds Targeting .
ACS Omega
December 2024
Laboratory of Cheminformatics, Faculty of Pharmacy, Universidade Federal de Goiás, Goiânia 74605-170, Brazil.
Article Synopsis
- Visceral leishmaniasis is a serious disease primarily found in low- and middle-income countries, with limited treatment options due to toxicity and drug resistance.
- Researchers developed a multitask learning (MTL) pipeline to predict the effectiveness of compounds against several species, screening about 1.3 million compounds and finding 20 potential candidates with significant antileishmanial activity.
- Three of these compounds showed strong efficacy and moderate safety, suggesting they could lead to new therapies, while the use of explainable models aids in understanding how these compounds work, potentially improving drug discovery for neglected tropical diseases.
Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy.
J Nanobiotechnology
December 2024
Precirix, Burg. Etienne Demunterlaan 3, Brussels, Matthias, B-1090, Belgium.
Background: Folate receptor alpha (FRα) overexpression is seen in many cancers. Radioligand therapy (RLT) has emerged as a promising tool to target FRα and has been investigated previously, but further progression was limited due to high kidney retention and, subsequently, toxicity. To circumvent this, we present here the development of a [I]I-GMIB-conjugated anti-human FRα (hFRα) single-domain antibody (sdAb), with intrinsically fast renal clearance and concomitant low kidney retention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!